This finding suggests that pre-existing cardiovascular pathology may adversely impact responsiveness to miRNA-based interventions, potentially due to chronic inflammation, endothelial dysfunction, or overlapping molecular mechanisms affecting both vascular and insulin signaling pathways. Here, INS is linked to endothelial dysfunction.